PPARG and Hypertension: Recently, considerable evidence points to a role of PPAR-γ and its agonists in inhibiting VSMC proliferation and preventing vascular remodeling in hypertension [20,21], restenosis [22,23], and atherosclerosis [23,24] in both early clinical trials and animal experiments.